Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1996 Apr;40(4):891-4.
doi: 10.1128/AAC.40.4.891.

Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States

Affiliations
Comparative Study

Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States

G V Doern et al. Antimicrob Agents Chemother. 1996 Apr.

Abstract

Three hundred fifty-two blood culture isolates of viridans group streptococci obtained from 43 U.S. medical centers during 1993 and 1994 were characterized. Included were 48 isolates of "Streptococcus milleri," 219 S. mitis isolates, 29 S. salivarius isolates, and 56 S. sanguis isolates. High-level penicillin resistance (MIC, > or = 4.0 micrograms/ml) was noted among 13.4% of the strains; for 42.9% of the strains, penicillin MICs were 0.25 to 2.0 micrograms/ml (i.e., intermediate resistance). In general, amoxicillin was slightly more active than penicillin. The rank order of activity for five cephalosporins versus viridans group streptococci was cefpodoxime = ceftriaxone > cefprozil = cefuroxime >> cephalexin. The percentages of isolates resistant (MIC, > or = 2 micrograms/ml) to these agents were 15, 17, 18, 20, and 96, respectively. The rates of resistance to erythromycin, tetracycline, and trimethoprim-sulfamethoxazole were 12 to 38%. Resistance to either chloramphenicol or ofloxacin was uncommon (i.e., < 1%). In general, among the four species, S. mitis was the most resistant and "S. milleri" was the most susceptible.

PubMed Disclaimer

References

    1. J Infect Dis. 1979 Sep;140(3):316-21 - PubMed
    1. Rev Infect Dis. 1979 Nov-Dec;1(6):955-66 - PubMed
    1. Lancet. 1984 Feb 18;1(8373):393 - PubMed
    1. Arch Intern Med. 1986 Dec;146(12):2361-3 - PubMed
    1. J Infect Dis. 1988 Apr;157(4):764-9 - PubMed

Publication types

LinkOut - more resources